Cite
Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties
MLA
Cseh, A., et al. Busulfan–fludarabine- or Treosulfan–fludarabine-Based Conditioning before Allogeneic HSCT from Matched Sibling Donors in Paediatric Patients with Sickle Cell Disease: A Study on Behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1439662669&authtype=sso&custid=ns315887.
APA
Cseh, A., Galimard, J.-E., de la Fuente, J., Isgro, A., Zecca, M., Garwer, B., Biffi, A., Aljurf, M., Sundin, M., Belendez, C., Locatelli, F., Balduzzi, A., Lawson, S., Sengeloev, H., Ifversen, M., Saccardi, R., Wynn, R., Lankester, A. C., Corbacioglu, S., … Locatelli F. (ORCID:0000-0002-7976-3654). (2023). Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.
Chicago
Cseh, A., J. -E. Galimard, J. de la Fuente, A. Isgro, M. Zecca, B. Garwer, A. Biffi, et al. 2023. “Busulfan–fludarabine- or Treosulfan–fludarabine-Based Conditioning before Allogeneic HSCT from Matched Sibling Donors in Paediatric Patients with Sickle Cell Disease: A Study on Behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1439662669&authtype=sso&custid=ns315887.